Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Cenexi reports an EBITDA breakeven for the quarter
Vasograin Plus represents a major advancement in the treatment of migraine
The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
Subscribe To Our Newsletter & Stay Updated
